Target Name: CCR2
NCBI ID: G729230
Review Report on CCR2 Target / Biomarker Content of Review Report on CCR2 Target / Biomarker
CCR2
Other Name(s): CCR2B | CCR2 variant A | CKR2 | MGC111760 | Chemokine CCR2B receptor | CCR2 variant B | OTTHUMP00000209947 | monocyte chemotactic protein 1 receptor | C-C chemokine receptor type 2 (isoform A) | C-C motif chemokine receptor 2 | C-C motif chemokine receptor 2, transcript variant B | Monocyte chemotactic protein 1 receptor | C-C chemokine receptor type 2 (isoform B) | Monocyte chemoattractant protein 1 receptor | CD192 | MCP-1-R | monocyte chemoattractant protein 1 receptor | CKR2B | MCP-1 receptor | C-C CKR-2 | OTTHUMP00000209949 | CCR-2 | chemokine (C-C motif) receptor 2 | CCR2_HUMAN | C-C chemokine receptor type 2 | CC-CKR-2 | CKR2A | FLJ78302 | CMKBR2 | MGC103828 | MGC168006 | CCR2A | C-C motif chemokine receptor 2, transcript variant A

CCR2: A Protein Targeted for Drug and Biomarker Development

CCR2 (Complement Component 2) is a protein that is expressed in many different tissues throughout the body. It is a key component of the complement system, which is a group of proteins that work together to help the immune system fight off infections. CCR2 is a protein that is often targeted by drugs because of its role in the immune response.

One way that CCR2 is used as a drug target is to inhibit its activity. Many drugs work by blocking the activity of CCR2, which can help to reduce the immune response and improve the effectiveness of the immune system. This is an important potential strategy for treating diseases that are characterized by an overactive immune system, such as cancer, autoimmune disorders, and infections.

Another way that CCR2 is used as a drug target is to use it as a biomarker. By measuring the level of CCR2 in a patient's body, doctors can get a sense of how strong the immune response is and whether the immune system is working properly. This can be important for diagnosing and monitoring certain types of cancer, as well as for evaluating the effectiveness of cancer treatments.

CCR2 is also a potential target for cancer because it is often expressed in the cells of cancerous tumors. This means that inhibiting the activity of CCR2 could be a promising new way to treat cancer. Many researchers are currently working to identify small molecules that can inhibit the activity of CCR2 and are exploring these compounds as potential new treatments for cancer.

CCR2 is also a potential target for other diseases because it is expressed in many different tissues throughout the body. This means that it is a promising target for a variety of diseases, including autoimmune disorders and infections. For example, some researchers are exploring the potential of CCR2 inhibitors as a new treatment for rheumatoid arthritis, an autoimmune disorder that affects millions of people around the world.

In addition to its potential as a drug and biomarker, CCR2 is also of interest to researchers because of its role in the immune response. Many researchers are interested in understanding how CCR2 contributes to the immune response and how it might be able to be used to improve the immune response in certain types of cancer. This could be an important area of research in the future, as the immune system plays a critical role in fighting off cancerous cells.

Overall, CCR2 is a protein that is of interest to researchers because of its role in the immune response and its potential as a drug and biomarker. As more research is done on CCR2, it is likely to become an increasingly important target for a variety of diseases.

Protein Name: C-C Motif Chemokine Receptor 2

Functions: Key functional receptor for CCL2 but can also bind CCL7 and CCL12 (PubMed:8146186, PubMed:8048929, PubMed:23408426). Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable). Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B (PubMed:23938203). Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation (By similarity). Facilitates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R (By similarity). Plays an important role in mediating peripheral nerve injury-induced neuropathic pain (By similarity). Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B (By similarity). Mediates the recruitment of macrophages and monocytes to the injury site following brain injury (By similarity)

The "CCR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55